Department of Urology, Yale School of Medicine, New Haven, Connecticut; Urologic Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA.
Cancer. 2013 Aug 15;119(16):2981-9. doi: 10.1002/cncr.28141. Epub 2013 May 14.
Partial nephrectomy (PN) and radical nephrectomy (RN) are standard treatments for a small renal mass. Retrospective studies suggest an overall survival (OS) advantage, however a randomized phase 3 trial suggests otherwise. The effects of both surgical modalities on OS were evaluated compared with controls.
A matched cohort study was performed using the Surveillance, Epidemiology, and End Results (SEER)-Medicare dataset. Individuals treated with PN or RN for localized renal cell carcinoma (RCC) measuring ≤4 cm were compared with 2 control groups (non-muscle-invasive bladder cancer (BCC) and noncancer controls (NCC). Using a greedy algorithm, RCC groups were matched with controls by demographics and comorbidities. OS for surgical groups and controls were compared. The cause of death was evaluated for cancer groups when differences in OS were noted.
Patients undergoing PN and RN were matched with controls. All cancer groups had >95% 10-year cancer-specific survival (CSS). Median OS was similar between RN (9.05 years) and BCC (8.67 years; P = .067) and NCC (8.77 years; P = .49). Median OS was improved for PN (10.45 years) compared with BCC (8.75 years; P<.001) and NCC controls (8.76 years; P<.001). A multivariate Cox hazards model demonstrated that PN improved OS compared with NCC (hazard ratio, 1.257; P<.001) and BCC (hazard ratio, 1.364; P<.001).
RN patients had similar OS compared with controls, suggesting that this treatment modality does not compromise survival. Patients undergoing PN had improved OS compared with controls, suggesting possible selection bias. The apparent survival advantage conferred by PN in SEER-Medicare case series is likely the result of selection bias involving unmeasured confounders.
部分肾切除术 (PN) 和根治性肾切除术 (RN) 是治疗小肾肿瘤的标准治疗方法。回顾性研究表明其具有整体生存 (OS) 优势,但一项随机 3 期试验则表明并非如此。本研究比较了两种手术方式对 OS 的影响。
本研究采用监测、流行病学和最终结果 (SEER)-医疗保险数据集进行匹配队列研究。比较了接受 PN 或 RN 治疗的局灶性肾细胞癌 (RCC) 患者(肿瘤直径≤4cm)与 2 个对照组(非肌层浸润性膀胱癌 (BCC) 和非癌症对照组 (NCC))。通过贪婪算法,根据人口统计学和合并症对 RCC 组与对照组进行匹配。比较手术组和对照组的 OS。当观察到 OS 差异时,评估癌症组的死亡原因。
接受 PN 和 RN 的患者与对照组相匹配。所有癌症组的 10 年癌症特异性生存率 (CSS) 均超过 95%。RN 组 (9.05 年) 与 BCC 组 (8.67 年;P = .067) 和 NCC 组 (8.77 年;P = .49) 的中位 OS 相似。与 BCC 组 (8.75 年;P<.001) 和 NCC 对照组 (8.76 年;P<.001) 相比,PN 组的中位 OS 改善。多变量 Cox 风险模型表明,与 NCC (风险比,1.257;P<.001) 和 BCC (风险比,1.364;P<.001) 相比,PN 改善了 OS。
与对照组相比,RN 患者的 OS 相似,表明该治疗方式不会影响生存。与对照组相比,接受 PN 的患者的 OS 得到改善,这表明可能存在选择偏倚。在 SEER-医疗保险病例系列中,PN 带来的明显生存优势可能是由于涉及未测量混杂因素的选择偏倚所致。